Nikolaus de Gregorio

Klinik für Frauenheilkunde — Germany

Medicine · Health Sciences

26h-index4.8kcitations238works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(110), Endometrial and Cervical Cancer Treatments(60), PARP inhibition in cancer therapy(46), BRCA gene mutations in cancer(37), Cervical Cancer and HPV Research(23)

Publications237 total

Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial
Journal of Clinical Oncology·2025· 1 cited
Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Supplementary Figure S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Supplementary Figure S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Supplementary Figure S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025Open Access
Atezolizumab versus Placebo in Kombination mit Bevacizumab und nicht-platinhaltiger Chemotherapie bei rezidivierendem Ovarialkarzinom: endgültige Gesamt- und progressionsfreie Überlebensergebnisse aus der AGO-OVAR 2.29/ENGOT-ov34-Studie
Geburtshilfe und Frauenheilkunde·2025
Abstract 6485: Prognostic impact of immune cells in vulvar carcinomas
Cancer Research·2025
Impact of lymphadenectomy rates in the quality assurance program in early ovarian cancer of the AGO Study Group – Real-world observations
European Journal of Surgical Oncology·2025· 1 citedOpen Access
TRAP (Twin Reversed Arterial Perfusion) Sequenz im dritten Trimenon
Zeitschrift für Geburtshilfe und Neonatologie·2025
Health-Related Quality Of Life And Symptom Burden In Patients With Newly Diagnosed Advanced Ovarian Cancer – Baseline Patient-Reported Outcome Results From The 3rd Interim Analysis Of The Non-Interventional SCOUT-1 Study (NOGGO Ov54, NCT04830709)
International Journal of Gynecological Cancer·2025
Prevalence Of Mutations According To Molecular And Genetic Profiling In Patients With Endometrial Cancer (AGO-TR2) DRKS Code: DRKS00030300
International Journal of Gynecological Cancer·2025
Gestationsbedingte Trophoblasterkrankungen
Elsevier eBooks·2025
Data from Ovarian Cancer–Specific <i>BRCA</i>-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial
2024Open Access
page 1 of 12Next →

Frequent Co-authors

Philipp Harter(21), Sven� Mahner(17), Felix Hilpert(17), Jalid Sehouli(16), Wolfgang Janni(16), Thomas W. P. Friedl(15), Klaus Baumann(13), Jacobus Pfisterer(13), Ulrich Canzler(12), Tanja Fehm(12), Werner Meier(12), Pauline Wimberger(12), Frederik Marmé(11), Alexander Burges(11), Lars Hanker(11), Andreas du Bois(10), Peter Hillemanns(10), Amelie de Gregorio(10), Annette Hasenburg(8), Peter A. Fasching(8)